Resverlogix Announces Combined RVX-208 Findings from SUSTAIN & ASSURE Phase 2b Trials

Resverlogix Announces Combined RVX-Resverlogix Announces Combined RVX- 208 Findings from SUSTAIN & ASSURE Phase 2b Trials PR Newswire CALGARY, Alberta, January 15, 2014 "RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX Resverlogix Corp. (TSX: RVX) today announced new information arising from its ongoing analysis of data from both the SUSTAIN and ASSURE trials in atherosclerotic patients with high risk for recurrent events. This analysis, performed by an independent firm focuses on the potential benefit of RVX-208, a first in class BET-inhibitor, to impact major adverse cardiac events (MACE) over a short time period of 6 months. When MACE data (n=499) from both SUSTAIN and ASSURE trials were combined, it demonstrated that treatment with RVX-208 lead to a significant reduction in MACE. RVX-208 treated patients (n=331), had less cumulative events of 6.74% vs. 15.09% (p=0.02) in the placebo treated group (n=168). Furthermore, in patients who had elevated CRP > 2.0mg/dL (n=283) the benefit of RVX-208 treatment of patients (n=179) appeared more striking with a cumulative event rate of 6.42% vs. 20.53% (p=0.007) in the placebo group (n=104). "Analysis of the ASSURE and SUSTAIN data arising from similar atherosclerotic patients with high risk of recurrent events provides important MACE information," stated Donald McCaffrey President and Chief Executive Officer of Resverlogix.